Study shows Cannabis terpenes may relieve chemotherapy-induced neuropathic pain

TUCSON, Arizona – May 29, 2024 (Investorideas.com Newswire) A new University of Arizona Health Sciences study published in the journal PAIN found that Cannabis sativa terpenes were as effective as morphine at reducing chronic neuropathic pain and a combination of the two analgesics further enhanced pain relief without negative side effects.

Some prior studies have shown that the Cannabis sativa plant and its two primary cannabinoids, tetrahydrocannabinol, or THC, and cannabidiol, or CBD, can be effective in managing chronic pain; however, the effects are generally moderate and can come with unwanted psychoactive side effects. Terpenes, the compounds that give plants their aroma and taste, offer an alternative path to pain relief without adverse side effects.

“A question that we’ve been very interested in is could terpenes be used to manage chronic pain?” said lead researcher John Streicher, PhD, a member of the Comprehensive Center for Pain & Addiction and a professor of pharmacology at the College of Medicine – Tucson. “What we found is that terpenes are really good at relieving a specific type of chronic pain with side effects that are low and manageable.”

Terpenes are found in all plants, and most plants have two dominant terpene species. Cannabis is unique in that it contains up to 150 terpenes with multiple terpenes acting as the dominant species. Streicher and the research team tested five terpenes that are found in moderate to high levels in Cannabis: alpha-humulene, beta-caryophyllene, beta-pinene, geraniol and linalool.

In a prior study, Streicher’s team found that four of those terpenes mimicked the effects of cannabinoids, including a reduction in the sensation of pain, in animal models of acute pain. For this study, they used a mouse model of chemotherapy-induced neuropathic pain, a type of chronic pain that occurs when highly toxic chemotherapy medications cause nerve damage that results in pain.

The terpenes were tested individually and compared with morphine. The research team found that each terpene was successful in reducing the sensation of pain at levels near to or above the peak effect of morphine. When the terpenes were combined with morphine, the pain-relieving effects of all five terpene/morphine combinations were significantly increased.

“That was really striking to us, but just because something relieves pain doesn’t necessarily mean it’s going to be a good therapy,” Streicher said.

Opioids are often used to treat many types of pain, but they can come with a host of unwanted side effects. Opioids activate the brain’s reward system, which is what can lead to addiction, and can cause tolerance, a condition that occurs when the body gets used to a medication and needs increasingly larger doses to have the same effect. Opioids also can cause respiratory depression, which can lead to death.

“We looked at other aspects of the terpenes, such as: Does this cause reward? Is this going to be addictive? Is it going to make you feel awful?” Streicher said. “What we found was yes, terpenes do relieve pain, and they also have a pretty good side effect profile.”

None of the terpenes had reward liability, making them a low risk for addiction. Some of the terpenes also did not cause aversive behaviors, which suggests they could be effective therapeutics without producing distressing side effects.

Finally, researchers tested different routes of terpene administration: injection, oral dosing and inhalation of vaporized pure terpenes. They found that when terpenes were given orally or inhaled, the effects were significantly reduced or absent.

“A lot of people vape or smoke terpenes as part of cannabis extracts that are available commercially in states where cannabis use is legal,” Streicher said “We were surprised to find that the inhalation route didn’t have an impact in this study, because there are a lot of at least anecdotal reports saying that you can get the effects of terpenes whether taken orally or inhaled. Part of the confounding factor is that terpenes smell quite nice and it’s hard to disguise that aroma, so people could be kind of having the psychosomatic placebo-style effect.”

Because this is the first paper to examine the side effects of terpenes, Streicher will be using its findings to inform the next stage of research – can terpenes block the reward potential of an opiate such as morphine while at the same time enhancing its pain-relief potential?

“This brings up the idea that you could have a combination therapy, an opioid with a high level of terpene, that could actually make the pain relief better while blocking the addiction potential of opioids,” Streicher said. “That’s what we are looking at now.”

Co-authors from the College of Medicine – Tucson’s Department of Pharmacology include former graduate student Abigail M. Schwarz, PhD; associate scientific investigator Attila Keresztes, PhD; and current or former undergraduate students Thai Bui, Ryan Hecksel, Adrian Peña, Brianna Lent, Martin Gamez-Rivera, Caleb Seekins, Kerry Chou, Taylor L. Appel and Fahad A. Al-Obeidi. Zhan-Gou Gao, MD, PhD, and Kenneth A. Jacobson, PhD, both from the National Institute of Diabetes and Digestive and Kidney Diseases, a division of the National Institutes of Health, also contributed to the research.

This work was supported in part by the National Institutes of Health under Award No. R01AT011517 and by the National Institute of Diabetes and Digestive and Kidney Diseases under Award No. ZIADK031117.

Please note that the University of Arizona Health Sciences is separately recognized from the University of Arizona, similar to other academic health centers across the country. The preferred first reference is University of Arizona Health Sciences; the preferred second reference is UArizona Health Sciences.

About the University of Arizona Health Sciences

The University of Arizona Health Sciences is one of the top-ranked academic medical centers in the southwestern United States, garnering more than $400 million in research grants and contracts annually. UArizona Health Sciences comprises the College of Health Sciences, College of Medicine – Phoenix, College of Medicine – Tucson, College of Nursing, R. Ken Coit College of Pharmacy, and Mel and Enid Zuckerman College of Public Health. Additionally, 15 centers are dedicated to excellence in cancer, neurodegenerative and respiratory diseases, pandemic preparedness, precision health care, and pain and addiction. UArizona Health Sciences employs approximately 3,000 people and has approximately 900 faculty members and 6,700 students on campuses in Tucson, Phoenix and Gilbert, Arizona.

About the University of Arizona College of Medicine – Tucson

The University of Arizona College of Medicine – Tucson is shaping the future of medicine through state-of-the-art medical education programs, groundbreaking research and advancements in patient care in Arizona and beyond. Founded in 1967, the college boasts more than 55 years of innovation, ranking among the top medical schools in the nation for research and primary care. Through the university’s partnership with Banner Health, one of the largest nonprofit health care systems in the country, the college is leading the way in academic medicine.

More Info:

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/

Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp

Get Great Trading Ideas and News Alerts

Guest posts and sponsored content – Got $100?

That’s all it takes to get an article published on Investor Ideas – Learn More